Premium
Use of fibrinogen to enhance the antitumor effect of OK‐432. A new approach to immunotherapy for colorectal carcinoma
Author(s) -
Monden Takushi,
Morimoto Hideki,
Shimano Takashi,
Yagyu Toshio,
Murotani Masahiro,
Nagaoka Hirohito,
Kawasaki Yasuhito,
Kobayashi Tetsuro,
Mori Takesada
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920201)69:3<636::aid-cncr2820690306>3.0.co;2-w
Subject(s) - medicine , fibrinogen , stroma , fibrin , infiltration (hvac) , colorectal cancer , aprotinin , immunotherapy , carcinoma , pathology , cancer research , cancer , immunology , immunohistochemistry , physics , thermodynamics
Abstract OK‐432 (5 KE), an immunomodulatory agent prepared from an attenuated strain of Streptococcus pyogenes , was dissolved in 1 ml of aprotinin (1000 KIE) and mixed with 80 mg of fibrinogen containing Factor XIII. A single intratumoral injection of the mixture was performed preoperatively under endoscopy in 20 patients with colorectal carcinoma. Postoperative histopathologic examinations revealed the formation of fibrin fibers at the site of injection and marked infiltration of inflammatory cells into the tumor stroma on the day after injection; the formation of granulomas containing many giant cells after 4 to 7 days; and extensive regression of tumor tissue after 14 days. This study suggests that the high concentration of exogenous fibrinogen gelatinized enough to trap OK‐432 in tumor stroma and that OK‐432 induced granulomatous hypersensitivity to degenerate tumor stroma, thereby causing regression of the tumors.